Global analysis of cardiovascular risk factors and their impact on health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Global Cardiovascular Risk Consortium (GCVRC) is an international collaboration that aggregates individual-level data from over 2 million participants across 133 cohorts in 39 countries. This observational study focuses on classical cardiovascular risk factors such as body mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, smoking, and diabetes, examining their effects on cardiovascular disease and all-cause mortality. By analyzing this extensive data, the GCVRC aims to develop region-specific strategies for cardiovascular disease prevention and treatment, enhancing global cardiovascular health outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Population-based individual-level data with available information on the classical cardiovascular risk factors including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes, as well as the outcomes of interest.

Exclusion Criteria:

* Participants with age below 18 years
* No information on the outcome of interest
* No information on the exposure of interest (CVD risk factors)
* History of CVD at baseline

Where it's running

• University Medical Center Hamburg-Eppendorf
  Hamburg, Free and Hanseatic City of Hamburg, Germany Recruiting

Study contacts

• Study coordinator: Prof. Dr. med. Stefan Blankenberg
• Email: s.blankenberg@uke.de
• Phone: +49 (0)40 741056800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease

  This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.

  Recruiting Odense University Hospital · Svendborg · NCT07878325

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Improving Care for underserved older Black patients with cardiovascular and other chronic conditions

  This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07748858

• 4D MRI parameters linked to cardiovascular and cancer disease outcomes

  This study tests whether 4D MRI measurements can predict how cardiovascular diseases and cancer will progress in adults undergoing routine cardiac MRI at a single Korean hospital.

  Recruiting Ulsan University Hospital · Ulsan, Ulsan · NCT07678606

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.